A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population

McDool, Emily; Mukuria, Clara; Brazier, John

doi:10.1007/s40273-021-01033-6

Cited by 8 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An explanation of these contrasting findings might be that the SF-6Dv2 has revised the dimension levels and could describe more health states than the SF-6Dv1 or the SF-6D derived from the SF-12. Consequently, the known group validity of the SF-6Dv2 might be improved, which has been confirmed by the previous evidence [47].…”

Section: Eq-5d-5lsupporting

confidence: 74%

“…Given that the SF-6Dv2 has been used in various countries [47,48], and the Chinese version of SF-6Dv2 and its corresponding utility value set has been developed recently [49,50], its measurement properties remain to be evaluated and compared with the EQ-5D-5L. Therefore, the aim of this study was to assess and compare the measurement properties of the SF-6Dv2 and EQ-5D-5L in a large-sample health survey among the Chinese population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey

Xie

Wang

et al. 2022

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background SF-6Dv2, the latest version of SF-6D, has been developed recently, and its measurement properties remain to be evaluated and compared with the EQ-5D-5L. The aim of this study was to assess and compare the measurement properties of the SF-6Dv2 and the EQ-5D-5L in a large-sample health survey among the Chinese population. Methods Data were obtained from the 2020 Health Service Survey in Tianjin, China. Respondents were randomly selected and invited to complete both the EQ-5D-5L and SF-6Dv2 through face-to-face interviews or self-administration. Health utility values were calculated by the Chinese value sets for the two measures. Ceiling and floor effects were firstly evaluated. Convergent validity and discriminate validity were examined using Spearman’s rank correlation and effect sizes, respectively. The agreement was assessed using intraclass correlation coefficients (ICC). Sensitivity was compared using relative efficiency and receiver operating characteristic. Results Among 19,177 respondents (49.3% male, mean age 55.2 years, ranged 18–102 years) included in this study, the mean utility was 0.939 (0.168) for EQ-5D-5L and 0.872 (0.184) for SF-6Dv2. A higher ceiling effect was observed in EQ-5D-5L than in SF-6Dv2 (72.8% vs. 36.1%). The Spearman’s rank correlation (range: 0.30–0.69) indicated an acceptable convergent validity between the dimensions of EQ-5D-5L and SF-6Dv2. The SF-6Dv2 showed slightly better discriminative capacities than the EQ-5D-5L (ES: 0.126–2.675 vs. 0.061–2.256). The ICC between the EQ-5D-5L and SF-6Dv2 utility values of the total sample was 0.780 (p < 0.05). The SF-6Dv2 had 29.0–179.2% higher efficiency than the EQ-5D-5L at distinguishing between respondents with different external health indicators, while the EQ-5D-5L was found to be 8.2% more efficient at detecting differences in self-reported health status than the SF-6Dv2. Conclusions Both the SF-6Dv2 and EQ-5D-5L have been demonstrated to be comparably valid and sensitive when used in Chinese population health surveys. The two measures may not be interchangeable given the moderate ICC and the systematic difference in utility values between the SF-6Dv2 and EQ-5D-5L. Further research is warranted to compare the test–retest reliability and responsiveness.

show abstract

Section: Eq-5d-5lsupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey

Xie

Wang

et al. 2022

Health Qual Life Outcomes

View full text Add to dashboard Cite

show abstract

“…There are substantial differences in the range of utilities between SF-6Dv1 (e.g. SF-6Dv1 does not have negative values whereas the minimal value for SF-6Dv2 was -0.574 in UK value set and − 0.685 in Australian value set [ 35 , 65 ]. The magnitude of declines in health utilities in NDs and GKDs sample may be underestimated.…”

Section: Discussionmentioning

confidence: 99%

QALYs and rare diseases: exploring the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing for childhood and adult-onset rare genetic conditions in Australia

Pan,

Wu,

Buchanan

et al. 2023

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background Genomic testing transforms the diagnosis and management of rare conditions. However, uncertainty exists on how to best measure genomic outcomes for informing healthcare priorities. Using the HTA-preferred method should be the starting point to improve the evidence-base. This study explores the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing across childhood and adult-onset genetic conditions. Method Self-reported patient-reported outcomes (PRO) were obtained from: primary caregivers of children with suspected neurodevelopmental disorders (NDs) or genetic kidney diseases (GKDs) (carers’ own PRO), adults with suspected GKDs using SF-12v2; adults with suspected complex neurological disorders (CNDs) using EQ-5D-5L; and adults with dilated cardiomyopathy (DCM) using AQol-8D. Responsiveness was assessed using the standardised response mean effect-size based on diagnostic (having a confirmed genomic diagnosis), personal (usefulness of genomic information to individuals or families), and clinical (clinical usefulness of genomic information) utility anchors. Results In total, 254 people completed PRO measures before genomic testing and after receiving results. For diagnostic utility, a nearly moderate positive effect size was identified by the AQoL-8D in adult DCM patients. Declines in physical health domains masked any improvements in mental or psychosocial domains in parents of children affected by NDs and adult CNDs and DCM patients with confirmed diagnosis. However, the magnitude of the changes was small and we did not find statistically significant evidence of these changes. No other responsiveness evidence related to diagnostic, clinical, and personal utility of genomic testing was identified. Conclusion Generic PRO measures may lack responsiveness to the diagnostic, clinical and personal outcomes of genomics, but further research is needed to establish their measurement properties and relevant evaluative space in the context of rare conditions. Expected declines in the physical health of people experiencing rare conditions may further challenge the conventional application of quality of life assessments.

show abstract

“…SF-6Dv2 is a new instrument that was developed based on 10 items of SF-36 to overcome some limitations of SF-6D [21,36]. By far, limited empirical evidence is available regarding its relative performance against the original SF-6D [37].…”

Section: Generic Health State Utility Instrumentsmentioning

confidence: 99%

Measuring the Wellbeing of Cancer Patients with Generic and Disease-Specific Instruments

Chen

Bulamu

McGrane

et al. 2023

Cancers

View full text Add to dashboard Cite

Different wellbeing measures have been used among cancer patients. This study aimed to first investigate the sensitivity of health state utility (HSU), capability, and subjective wellbeing (SWB) instruments in cancer. A cancer-specific instrument (QLQ-C30) was included and transferred onto the cancer-specific HSU scores. Furthermore, it examined the relative importance of key life domains explaining overall life satisfaction. Data were drawn from the Multi-instrument Comparison survey. Linear regression was used to explore the extent to which the QLQ-C30 sub-scales explain HSU and SWB. Kernel-based Regularized Least Squares (KRLS), a machine learning method, was used to explore the life domain importance of cancer patients. As expected, the QLQ-C30 sub-scales explained the vast majority of the variance in its derived cancer-specific HSU (R2 = 0.96), followed by generic HSU instruments (R2 of 0.65–0.73) and SWB and capability instruments (R2 of 0.33–0.48). The cancer-specific measure was more closely correlated with generic HSU than SWB measures, owing to the construction of these instruments. In addition to health, life achievements, relationships, the standard of living, and future security all play an important role in explaining the overall life satisfaction of cancer patients.

show abstract

A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population

Cited by 8 publications

References 28 publications

Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey

Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey

QALYs and rare diseases: exploring the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing for childhood and adult-onset rare genetic conditions in Australia

Measuring the Wellbeing of Cancer Patients with Generic and Disease-Specific Instruments

Contact Info

Product

Resources

About